Objective: To determine the effect of bedtime high-dose amantadine extended release (Gocovri) in 50 consecutive patients experiencing motor fluctuations and dyskinesia.

Background: Amantadine extended release (Gocovri) has established efficacy and tolerability in clinical trials, with reduced dyskinesia, reduced OFF time, and improved ON time without troublesome dyskinesia. The PKG watch (Global Kinetics) is a wearable device that can provide continuous monitoring over six days of bradykinesia, dyskinesia, fluctuations, tremor, and immobility.

Methods: In 50 consecutive patients who were prescribed amantadine extended release (Gocovri), we used the PKG to evaluate bradykinesia, dyskinesia, and fluctuation indices before and after beginning treatment.

Results: Evaluation of the PKG demonstrated that most patients had reduced dyskinesia with a lower fluctuation index. Over 50% of patients had reduction in both dyskinesia and also bradykinesia.

Conclusions: Using the wearable PKG, bedtime high-dose amantadine extended release (Gocovri), reduced fluctuations, with improvement of both dyskinesia and bradykinesia. Wearable devices can be clinically useful in evaluating responses to treatment.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/amantadine-extended-release-gocovri-reduces-dyskinesia-and-bradykinesia-evaluation-of-clinical-response-with-the-wearable-pkg-personal-kinetigraph-watch/